Compare Piramal Healthcare with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs NATCO PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES NATCO PHARMA PIRAMAL ENTERPRISES/
NATCO PHARMA
 
P/E (TTM) x 15.5 15.6 99.6% View Chart
P/BV x 1.0 3.1 32.2% View Chart
Dividend Yield % 1.8 1.5 123.5%  

Financials

 PIRAMAL ENTERPRISES   NATCO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
NATCO PHARMA
Mar-18
PIRAMAL ENTERPRISES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,080 305.8%   
Low Rs1,797671 267.7%   
Sales per share (Unadj.) Rs716.5592.1 121.0%  
Earnings per share (Unadj.) Rs79.7188.4 42.3%  
Cash flow per share (Unadj.) Rs107.9206.3 52.3%  
Dividends per share (Unadj.) Rs28.008.25 339.4%  
Dividend yield (eoy) %1.10.9 116.6%  
Book value per share (Unadj.) Rs1,477.5833.6 177.2%  
Shares outstanding (eoy) m184.4536.90 499.9%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x3.61.5 240.6%   
Avg P/E ratio x32.04.6 688.3%  
P/CF ratio (eoy) x23.64.2 556.8%  
Price / Book Value ratio x1.71.1 164.3%  
Dividend payout %35.14.4 802.3%   
Avg Mkt Cap Rs m470,29232,311 1,455.5%   
No. of employees `0007.84.8 161.9%   
Total wages/salary Rs m22,5043,256 691.1%   
Avg. sales/employee Rs Th16,899.44,522.5 373.7%   
Avg. wages/employee Rs Th2,877.7674.0 427.0%   
Avg. net profit/employee Rs Th1,879.91,439.0 130.6%   
INCOME DATA
Net Sales Rs m132,15321,848 604.9%  
Other income Rs m3,128404 774.3%   
Total revenues Rs m135,28122,252 608.0%   
Gross profit Rs m66,2909,284 714.0%  
Depreciation Rs m5,202662 785.7%   
Interest Rs m44,097154 28,634.7%   
Profit before tax Rs m20,1198,872 226.8%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,920 448.5%   
Profit after tax Rs m14,7016,952 211.5%  
Gross profit margin %50.242.5 118.0%  
Effective tax rate %42.821.6 197.8%   
Net profit margin %11.131.8 35.0%  
BALANCE SHEET DATA
Current assets Rs m122,74221,307 576.1%   
Current liabilities Rs m310,8105,920 5,250.2%   
Net working cap to sales %-142.370.4 -202.1%  
Current ratio x0.43.6 11.0%  
Inventory Days Days2373 31.5%  
Debtors Days Days39107 36.5%  
Net fixed assets Rs m116,90414,986 780.1%   
Share capital Rs m369369 100.0%   
"Free" reserves Rs m272,16130,353 896.7%   
Net worth Rs m272,53030,760 886.0%   
Long term debt Rs m270,1960-   
Total assets Rs m856,26137,151 2,304.8%  
Interest coverage x1.558.6 2.5%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.6 26.2%   
Return on assets %6.919.1 35.9%  
Return on equity %5.422.6 23.9%  
Return on capital %12.429.3 42.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20010,322 147.3%   
Fx outflow Rs m4,8892,978 164.1%   
Net fx Rs m10,3127,343 140.4%   
CASH FLOW
From Operations Rs m-115,9754,636 -2,501.6%  
From Investments Rs m-8,265-11,155 74.1%  
From Financial Activity Rs m107,5256,509 1,651.9%  
Net Cashflow Rs m-16,650-18 92,501.1%  

Share Holding

Indian Promoters % 52.9 52.0 101.7%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.0 7.8 51.0%  
FIIs % 26.6 16.6 160.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 26.0 63.5%  
Shareholders   93,274 25,395 367.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   STERLING BIOTECH  NOVARTIS  DR. DATSONS LABS  ORCHID PHARMA LTD  SANOFI INDIA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 18, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS